Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting

Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains l...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in medical oncology 2023-01, Vol.15, p.17588359231152847
Main Authors: Assié, Jean-Baptiste, Chouaïd, Christos, Nunes, Hilario, Reynaud, Dorothée, Gaudin, Anne-Françoise, Grumberg, Valentine, Jolivel, Ronan, Jouaneton, Baptiste, Cotté, François-Emery, Duchemann, Boris
Format: Article
Language:English
Subjects:
Cancer
Clinical trials
Comorbidity
Immunotherapy
Life Sciences
Lung cancer
Lung diseases
Monoclonal antibodies
Non-small cell lung carcinoma
Original Research
Patients
Santé publique et épidémiologie
Small cell lung carcinoma
Survival analysis
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803
cites cdi_FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803
container_end_page
container_issue
container_start_page 17588359231152847
container_title Therapeutic advances in medical oncology
container_volume 15
creator Assié, Jean-Baptiste
Chouaïd, Christos
Nunes, Hilario
Reynaud, Dorothée
Gaudin, Anne-Françoise
Grumberg, Valentine
Jolivel, Ronan
Jouaneton, Baptiste
Cotté, François-Emery
Duchemann, Boris
description Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. Patients and methods: The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015–2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan–Meier survival analysis. Results: Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (p 
doi_str_mv 10.1177/17588359231152847
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aaeb77ceaeb54391980a9b65f9f243ac</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_17588359231152847</sage_id><doaj_id>oai_doaj_org_article_aaeb77ceaeb54391980a9b65f9f243ac</doaj_id><sourcerecordid>2773718782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803</originalsourceid><addsrcrecordid>eNp1ks1u1DAQxyMEomXhAbggS1zgkGLHTmxfkKoKaKWVeoGzNbGdXa-SeLGdXfEovC0OWUpbxMW2Zv7zmw9PUbwm-IIQzj8QXgtBa1lRQupKMP6kOJ9t5Wx8eu99VryIcYdx07AGPy_OaMMZrSt6Xvy8nZL2g0Wd73t_dOMGje7g-2mAFqVgIQ12TMiNaA_J5WdER5e2CMwBRm0NGv1YxgH6Hmmbj37KBD27AoLRoMz2oXUmE5INMbnk4KQyLlqIdmYDypn68uhDb1C0KeU6XhbPOuijfXW6V8W3z5--Xl2X69svN1eX61Iz2aSyJkyDFLatKe0azHO7jInG6JYToWvbdrJt664yxhDZiq6TQAQVgjFobCUwXRU3C9d42Kl9cAOEH8qDU78NPmwUhOR0bxWAbTnXNl81o5JIgUG2Td3JrmIUdGZ9XFj7qR2s0XleAfoH0Iee0W3Vxh-UFJLSmmTA-wWwfRR2fblWsw0zwggR-DBr352SBf99sjGpwcX5E2C0foqq4pzmGXBRZenbR9Kdn8KYx6oqWeG8CyKPb1WQRaWDjzHY7q4CgtW8cOqfhcsxb-53fBfxZ8Oy4GIRRNjYv2n_T_wFSz3g8w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920435853</pqid></control><display><type>article</type><title>Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting</title><source>Publicly Available Content Database</source><source>Sage Journals GOLD Open Access 2024</source><source>PubMed Central</source><creator>Assié, Jean-Baptiste ; Chouaïd, Christos ; Nunes, Hilario ; Reynaud, Dorothée ; Gaudin, Anne-Françoise ; Grumberg, Valentine ; Jolivel, Ronan ; Jouaneton, Baptiste ; Cotté, François-Emery ; Duchemann, Boris</creator><creatorcontrib>Assié, Jean-Baptiste ; Chouaïd, Christos ; Nunes, Hilario ; Reynaud, Dorothée ; Gaudin, Anne-Françoise ; Grumberg, Valentine ; Jolivel, Ronan ; Jouaneton, Baptiste ; Cotté, François-Emery ; Duchemann, Boris</creatorcontrib><description>Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. Patients and methods: The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015–2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan–Meier survival analysis. Results: Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (p &lt; 0.05) and had more comorbidities (p &lt; 0.001). There was no significant difference between ILD and non-ILD groups for median TTD (2.5 versus 2.8 months; p = 0.6) or median OS (9.6 versus 11.9 months; p = 0.1). Median OS in AI/G ILD (n = 14), other known causes ILD (n = 75), and idiopathic ILD (n = 59) were 8.6, 10.7, and 9.6 months, respectively. Conclusion: In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.</description><identifier>ISSN: 1758-8359</identifier><identifier>ISSN: 1758-8340</identifier><identifier>EISSN: 1758-8359</identifier><identifier>DOI: 10.1177/17588359231152847</identifier><identifier>PMID: 36743523</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Cancer ; Clinical trials ; Comorbidity ; Immunotherapy ; Life Sciences ; Lung cancer ; Lung diseases ; Monoclonal antibodies ; Non-small cell lung carcinoma ; Original Research ; Patients ; Santé publique et épidémiologie ; Small cell lung carcinoma ; Survival analysis ; Targeted cancer therapy</subject><ispartof>Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231152847</ispartof><rights>The Author(s), 2023</rights><rights>The Author(s), 2023.</rights><rights>The Author(s), 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>The Author(s), 2023 2023 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803</citedby><cites>FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803</cites><orcidid>0000-0002-4290-5524</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893351/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2920435853?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,21965,25752,27852,27923,27924,37011,37012,44589,44944,45332,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36743523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.u-pec.fr/hal-04141180$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Assié, Jean-Baptiste</creatorcontrib><creatorcontrib>Chouaïd, Christos</creatorcontrib><creatorcontrib>Nunes, Hilario</creatorcontrib><creatorcontrib>Reynaud, Dorothée</creatorcontrib><creatorcontrib>Gaudin, Anne-Françoise</creatorcontrib><creatorcontrib>Grumberg, Valentine</creatorcontrib><creatorcontrib>Jolivel, Ronan</creatorcontrib><creatorcontrib>Jouaneton, Baptiste</creatorcontrib><creatorcontrib>Cotté, François-Emery</creatorcontrib><creatorcontrib>Duchemann, Boris</creatorcontrib><title>Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting</title><title>Therapeutic advances in medical oncology</title><addtitle>Ther Adv Med Oncol</addtitle><description>Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. Patients and methods: The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015–2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan–Meier survival analysis. Results: Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (p &lt; 0.05) and had more comorbidities (p &lt; 0.001). There was no significant difference between ILD and non-ILD groups for median TTD (2.5 versus 2.8 months; p = 0.6) or median OS (9.6 versus 11.9 months; p = 0.1). Median OS in AI/G ILD (n = 14), other known causes ILD (n = 75), and idiopathic ILD (n = 59) were 8.6, 10.7, and 9.6 months, respectively. Conclusion: In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.</description><subject>Cancer</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Monoclonal antibodies</subject><subject>Non-small cell lung carcinoma</subject><subject>Original Research</subject><subject>Patients</subject><subject>Santé publique et épidémiologie</subject><subject>Small cell lung carcinoma</subject><subject>Survival analysis</subject><subject>Targeted cancer therapy</subject><issn>1758-8359</issn><issn>1758-8340</issn><issn>1758-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks1u1DAQxyMEomXhAbggS1zgkGLHTmxfkKoKaKWVeoGzNbGdXa-SeLGdXfEovC0OWUpbxMW2Zv7zmw9PUbwm-IIQzj8QXgtBa1lRQupKMP6kOJ9t5Wx8eu99VryIcYdx07AGPy_OaMMZrSt6Xvy8nZL2g0Wd73t_dOMGje7g-2mAFqVgIQ12TMiNaA_J5WdER5e2CMwBRm0NGv1YxgH6Hmmbj37KBD27AoLRoMz2oXUmE5INMbnk4KQyLlqIdmYDypn68uhDb1C0KeU6XhbPOuijfXW6V8W3z5--Xl2X69svN1eX61Iz2aSyJkyDFLatKe0azHO7jInG6JYToWvbdrJt664yxhDZiq6TQAQVgjFobCUwXRU3C9d42Kl9cAOEH8qDU78NPmwUhOR0bxWAbTnXNl81o5JIgUG2Td3JrmIUdGZ9XFj7qR2s0XleAfoH0Iee0W3Vxh-UFJLSmmTA-wWwfRR2fblWsw0zwggR-DBr352SBf99sjGpwcX5E2C0foqq4pzmGXBRZenbR9Kdn8KYx6oqWeG8CyKPb1WQRaWDjzHY7q4CgtW8cOqfhcsxb-53fBfxZ8Oy4GIRRNjYv2n_T_wFSz3g8w</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Assié, Jean-Baptiste</creator><creator>Chouaïd, Christos</creator><creator>Nunes, Hilario</creator><creator>Reynaud, Dorothée</creator><creator>Gaudin, Anne-Françoise</creator><creator>Grumberg, Valentine</creator><creator>Jolivel, Ronan</creator><creator>Jouaneton, Baptiste</creator><creator>Cotté, François-Emery</creator><creator>Duchemann, Boris</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Journals</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4290-5524</orcidid></search><sort><creationdate>20230101</creationdate><title>Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting</title><author>Assié, Jean-Baptiste ; Chouaïd, Christos ; Nunes, Hilario ; Reynaud, Dorothée ; Gaudin, Anne-Françoise ; Grumberg, Valentine ; Jolivel, Ronan ; Jouaneton, Baptiste ; Cotté, François-Emery ; Duchemann, Boris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Monoclonal antibodies</topic><topic>Non-small cell lung carcinoma</topic><topic>Original Research</topic><topic>Patients</topic><topic>Santé publique et épidémiologie</topic><topic>Small cell lung carcinoma</topic><topic>Survival analysis</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Assié, Jean-Baptiste</creatorcontrib><creatorcontrib>Chouaïd, Christos</creatorcontrib><creatorcontrib>Nunes, Hilario</creatorcontrib><creatorcontrib>Reynaud, Dorothée</creatorcontrib><creatorcontrib>Gaudin, Anne-Françoise</creatorcontrib><creatorcontrib>Grumberg, Valentine</creatorcontrib><creatorcontrib>Jolivel, Ronan</creatorcontrib><creatorcontrib>Jouaneton, Baptiste</creatorcontrib><creatorcontrib>Cotté, François-Emery</creatorcontrib><creatorcontrib>Duchemann, Boris</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutic advances in medical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Assié, Jean-Baptiste</au><au>Chouaïd, Christos</au><au>Nunes, Hilario</au><au>Reynaud, Dorothée</au><au>Gaudin, Anne-Françoise</au><au>Grumberg, Valentine</au><au>Jolivel, Ronan</au><au>Jouaneton, Baptiste</au><au>Cotté, François-Emery</au><au>Duchemann, Boris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting</atitle><jtitle>Therapeutic advances in medical oncology</jtitle><addtitle>Ther Adv Med Oncol</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>15</volume><spage>17588359231152847</spage><pages>17588359231152847-</pages><issn>1758-8359</issn><issn>1758-8340</issn><eissn>1758-8359</eissn><abstract>Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. Patients and methods: The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015–2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan–Meier survival analysis. Results: Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (p &lt; 0.05) and had more comorbidities (p &lt; 0.001). There was no significant difference between ILD and non-ILD groups for median TTD (2.5 versus 2.8 months; p = 0.6) or median OS (9.6 versus 11.9 months; p = 0.1). Median OS in AI/G ILD (n = 14), other known causes ILD (n = 75), and idiopathic ILD (n = 59) were 8.6, 10.7, and 9.6 months, respectively. Conclusion: In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>36743523</pmid><doi>10.1177/17588359231152847</doi><orcidid>https://orcid.org/0000-0002-4290-5524</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1758-8359
ispartof Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231152847
issn 1758-8359
1758-8340
1758-8359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aaeb77ceaeb54391980a9b65f9f243ac
source Publicly Available Content Database; Sage Journals GOLD Open Access 2024; PubMed Central
subjects Cancer
Clinical trials
Comorbidity
Immunotherapy
Life Sciences
Lung cancer
Lung diseases
Monoclonal antibodies
Non-small cell lung carcinoma
Original Research
Patients
Santé publique et épidémiologie
Small cell lung carcinoma
Survival analysis
Targeted cancer therapy
title Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A59%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20following%20nivolumab%20treatment%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20and%20comorbid%20interstitial%20lung%20disease%20in%20a%20real-world%20setting&rft.jtitle=Therapeutic%20advances%20in%20medical%20oncology&rft.au=Assi%C3%A9,%20Jean-Baptiste&rft.date=2023-01-01&rft.volume=15&rft.spage=17588359231152847&rft.pages=17588359231152847-&rft.issn=1758-8359&rft.eissn=1758-8359&rft_id=info:doi/10.1177/17588359231152847&rft_dat=%3Cproquest_doaj_%3E2773718782%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c496t-514ca98eb533f6078354486dcb718c5ebf9bb5f2ddd19b8ff9a1838844a6e2803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2920435853&rft_id=info:pmid/36743523&rft_sage_id=10.1177_17588359231152847&rfr_iscdi=true